Hulio is a prescription medication known as a biosimilar to adalimumab, which is marketed under the brand name Humira among others. It is designed to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, and ulcerative colitis. Hulio works by inhibiting tumor necrosis factor (TNF), a substance in the body that causes inflammation and can lead to the symptoms associated with these conditions. As a biosimilar, Hulio has been shown to have no clinically meaningful differences in purity, potency, and safety compared to its reference product, Humira. It is administered through subcutaneous injection and offers an alternative option for patients requiring TNF inhibitor therapy.